Policy tailwinds and precision medicine breakthroughs are pushing healthcare stocks like Tempus AI and CRISPR Therapeutics ...

Genome editing technologies like CRISPR-Cas9 have transformed biology, medicine, and agriculture, but concerns remain about unintended edits at off-target DNA sites. These off-target effects can cause ...

Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FDA approval for their gene-editing therapy Casgevy (exa-cel) to treat transfusion-dependent beta thalassemia (TDT). The approval comes ...

KJ Muldoon recently made history by becoming the first patient to receive a personalized CRISPR gene therapy, designed specifically for the genetic mutations causing his rare metabolic disease. Now, a ...

CRISPR Therapeutics has reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its in vivo liver editing prospect CTX310, encouraging the company to forge ...

Global clinical-stage biotech company HuidaGene Therapeutics has received FDA clearance to move forward with its application for its investigational drug, a CRISPR/Cas13 RNA-editing therapy to treat ...

SAN DIEGO & BRISBANE, Calif.--(BUSINESS WIRE)--VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a non-exclusive license agreement with Mammoth Biosciences, ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...

CRISPR has the power to correct genetic mutations, but current delivery methods are either unsafe or inefficient, keeping the technology from reaching its full medical potential. With the power to ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Adam Feuerstein is a ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $61.67, marking a +2.24% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.59%. On the other hand, the ...